William Gordon Frankle
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
William Gordon Frankle has a total of 189 co-authors. Here are the top co-authors by number of shared publications:
Marc Laruelle
Department of Psychiatry, Columbia University and New York State Psychiatric Institute, New York, NY, USA; Department of Neurosciences, Imperial College, London, UK
19 shared publicationsChester A. Mathis
Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania
15 shared publicationsRajesh Narendran
Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania
15 shared publications- Rajesh Narendran
Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania
15 shared publications Anissa Abi-Dargham
Department of Psychiatry, Columbia University and New York State Psychiatric Institute, New York, NY, USA
14 shared publicationsN. Scott Mason
Department of Radiology, University of Pittsburgh, Pittsburgh, Pennsylvania
13 shared publications
Latest Publications
- 7 July 2025
- Published by Springer Nature in Community Mental Health Journal
- Vol. 61 (8) , 1422-1428
The EnTRy Program: Expanding Coordinated Specialty Care Beyond Early Psychosis
This study aims to evaluate the quality and potential clinical benefits of a novel program, called the Enhanced Treatment and Recovery (EnTRy) Program, which provides Coordinated Specialty Care (CSC) without limits on diagnosis, age, or treatment time to individuals with serious mental illnesses (SMI). To assess recovery of participants, we compared the baseline Substance Abuse and Mental Health Services Administration (SAMSHA) National Outcome Measures (NOMs) in patients enrolled in EnTRy to that at 6 months and 12 months. To explore whether EnTRy provided benefits over standard treatment, we compared the time engaged in treatment for the EnTRy cohort with that of a historic sample from the same clinical site. Participants were significantly less likely to have a psychiatric hospitalization in the past 30 days during follow-up assessment at 6 months (19% at baseline, 1% at 6 months, (χ2 (1, N = 1006) = 91, pχ2 (1, N = 486) = 37.633, pχ2 (1, N = 1004) = 86.808, p < 0.0001) and at 12 months (16% at baseline, 2% at 12 months, χ2(1, N = 486) = 32.387, p= 0.0001). Patients enrolled in the EnTRy program remained engaged with care for significantly longer than a historical sample (p< 0.0001 by Mantel-Cox logrank) with a logrank hazard ratio of 2.0 (CI 1.65– 2.43). Age and diagnosis-unlimited CSC may be particularly effective for individuals with SMI who recently received hospital level care and may help maintain gains in individuals who have aged out of programs dedicated to first episode psychiatric illness.
- 7 July 2025
- Published by Springer Nature in Community Mental Health Journal
- Vol. 61 (8) , 1422-1428
The EnTRy Program: Expanding Coordinated Specialty Care Beyond Early Psychosis
This study aims to evaluate the quality and potential clinical benefits of a novel program, called the Enhanced Treatment and Recovery (EnTRy) Program, which provides Coordinated Specialty Care (CSC) without limits on diagnosis, age, or treatment time to individuals with serious mental illnesses (SMI). To assess recovery of participants, we compared the baseline Substance Abuse and Mental Health Services Administration (SAMSHA) National Outcome Measures (NOMs) in patients enrolled in EnTRy to that at 6 months and 12 months. To explore whether EnTRy provided benefits over standard treatment, we compared the time engaged in treatment for the EnTRy cohort with that of a historic sample from the same clinical site. Participants were significantly less likely to have a psychiatric hospitalization in the past 30 days during follow-up assessment at 6 months (19% at baseline, 1% at 6 months, (χ2 (1, N = 1006) = 91, pχ2 (1, N = 486) = 37.633, pχ2 (1, N = 1004) = 86.808, p < 0.0001) and at 12 months (16% at baseline, 2% at 12 months, χ2(1, N = 486) = 32.387, p= 0.0001). Patients enrolled in the EnTRy program remained engaged with care for significantly longer than a historical sample (p< 0.0001 by Mantel-Cox logrank) with a logrank hazard ratio of 2.0 (CI 1.65– 2.43). Age and diagnosis-unlimited CSC may be particularly effective for individuals with SMI who recently received hospital level care and may help maintain gains in individuals who have aged out of programs dedicated to first episode psychiatric illness.
- 14 May 2022
- Published by Elsevier in Biological Psychiatry
- Vol. 92 (10) , 791-799
Prefrontal and Striatal Dopamine Release Are Inversely Correlated in Schizophrenia
- 14 May 2022
- Published by Elsevier in Biological Psychiatry
- Vol. 92 (10) , 791-799
Prefrontal and Striatal Dopamine Release Are Inversely Correlated in Schizophrenia
- 1 March 2021
- Published by Wolters Kluwer Health in Journal of Psychiatric Practice
- Vol. 27 (2) , 137-144
Suspected Recurrence of Symptomatic COVID-19: Management During Inpatient Psychiatric Treatment
The widespread prevalence of coronavirus disease 2019 (COVID-19) means that inpatient psychiatric units will necessarily manage patients who have COVID-19 that is comorbid with acute psychiatric symptoms. We report a case of recurrence of respiratory symptoms and positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reverse transcription-polymerase chain reaction (RT-PCR) testing in a patient on an inpatient psychiatric unit occurring 42 days after the initial positive SARS-CoV-2 RT-PCR test, 38 days after initial symptom resolution, and 30 days after the first of 3 negative SARS-CoV-2 RT-PCR tests. Over the course of the admission, the patient was safely initiated on clozapine. Recent literature on COVID-19’s potential recurrence and neuropsychiatric effects is reviewed and implications for the management of COVID-19 on inpatient psychiatric units are discussed. In the era of COVID-19 and our still-developing understanding of this illness, psychiatrists’ role as advocates and collaborators in our patients’ physical health care has become even more critical.
- 1 March 2021
- Published by Wolters Kluwer Health in Journal of Psychiatric Practice
- Vol. 27 (2) , 137-144
Suspected Recurrence of Symptomatic COVID-19: Management During Inpatient Psychiatric Treatment
The widespread prevalence of coronavirus disease 2019 (COVID-19) means that inpatient psychiatric units will necessarily manage patients who have COVID-19 that is comorbid with acute psychiatric symptoms. We report a case of recurrence of respiratory symptoms and positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) reverse transcription-polymerase chain reaction (RT-PCR) testing in a patient on an inpatient psychiatric unit occurring 42 days after the initial positive SARS-CoV-2 RT-PCR test, 38 days after initial symptom resolution, and 30 days after the first of 3 negative SARS-CoV-2 RT-PCR tests. Over the course of the admission, the patient was safely initiated on clozapine. Recent literature on COVID-19’s potential recurrence and neuropsychiatric effects is reviewed and implications for the management of COVID-19 on inpatient psychiatric units are discussed. In the era of COVID-19 and our still-developing understanding of this illness, psychiatrists’ role as advocates and collaborators in our patients’ physical health care has become even more critical.
- Open Access
- 1 September 2020
- Published by Royal College of Psychiatrists in BJPsych Open
- Vol. 6 (5) , e99
In-patient psychiatry management of COVID-19: rates of asymptomatic infection and on-unit transmission
Background: New York City's first case of SARS-associated coronavirus (SARS-CoV-2) disease 2019 (COVID-19) was identified on 1 March 2020, prompting rapid restructuring of hospital-based services to accommodate the increasing numbers of medical admissions. Non-essential services were eliminated but in-patient treatment of psychiatric illnesses was necessarily maintained. Aims: To detail the response of the NYU Langone Health in-patient psychiatric services to the COVID-19 outbreak from 1 March to 1 May 2020. Method: Process improvement/quality improvement study. Results: Over this time period, our two in-patient psychiatric units (57 total beds) treated 238 patients, including COVID-19-positive and -negative individuals. Testing for COVID-19 was initially limited to symptomatic patients but expanded over the 62-day time frame. In total, 122 SARS-CoV-2 polymerase chain reaction (PCR) tests were performed in 98 patients. We observed an overall rate of COVID-19 infection of 15.6% in the patients who were tested, with an asymptomatic positive rate of 13.7%. Although phased roll-out of testing impaired the ability to fully track on-unit transmission of COVID-19, 3% of cases were clearly identified as results of on-unit transmission. Conclusions: Our experience indicates that, with appropriate precautions, patients in need of in-patient psychiatric admission who have COVID-19 can be safely managed. We provide suggested guidelines for COVID-19 management on in-patient psychiatric units which incorporate our own experiences as well as published recommendations.
- 1 September 2020
- Published by Royal College of Psychiatrists in BJPsych Open
- Vol. 6 (5) , e99
Open AccessIn-patient psychiatry management of COVID-19: rates of asymptomatic infection and on-unit transmission
Background: New York City's first case of SARS-associated coronavirus (SARS-CoV-2) disease 2019 (COVID-19) was identified on 1 March 2020, prompting rapid restructuring of hospital-based services to accommodate the increasing numbers of medical admissions. Non-essential services were eliminated but in-patient treatment of psychiatric illnesses was necessarily maintained. Aims: To detail the response of the NYU Langone Health in-patient psychiatric services to the COVID-19 outbreak from 1 March to 1 May 2020. Method: Process improvement/quality improvement study. Results: Over this time period, our two in-patient psychiatric units (57 total beds) treated 238 patients, including COVID-19-positive and -negative individuals. Testing for COVID-19 was initially limited to symptomatic patients but expanded over the 62-day time frame. In total, 122 SARS-CoV-2 polymerase chain reaction (PCR) tests were performed in 98 patients. We observed an overall rate of COVID-19 infection of 15.6% in the patients who were tested, with an asymptomatic positive rate of 13.7%. Although phased roll-out of testing impaired the ability to fully track on-unit transmission of COVID-19, 3% of cases were clearly identified as results of on-unit transmission. Conclusions: Our experience indicates that, with appropriate precautions, patients in need of in-patient psychiatric admission who have COVID-19 can be safely managed. We provide suggested guidelines for COVID-19 management on in-patient psychiatric units which incorporate our own experiences as well as published recommendations.
- 12 April 2020
- Published by Elsevier in Biological Psychiatry
- Vol. 88 (10) , 788-796
Imaging Cortical Dopamine Transmission in Cocaine Dependence: A [11C]FLB 457–Amphetamine Positron Emission Tomography Study
- 12 April 2020
- Published by Elsevier in Biological Psychiatry
- Vol. 88 (10) , 788-796
Imaging Cortical Dopamine Transmission in Cocaine Dependence: A [11C]FLB 457–Amphetamine Positron Emission Tomography Study
- 1 February 2020
- Published by Elsevier in Biological Psychiatry
- Vol. 87 (3) , 197-199
Distinguishing Schizophrenia Subtypes: Can Dopamine Imaging Improve the Signal-to-Noise Ratio?
- 1 February 2020
- Published by Elsevier in Biological Psychiatry
- Vol. 87 (3) , 197-199
Distinguishing Schizophrenia Subtypes: Can Dopamine Imaging Improve the Signal-to-Noise Ratio?
Failure to detect amphetamine‐induced dopamine release in the cortex with [11C]FLB 457 positron emission tomography (PET): Methodological considerations
Studies in nonhuman primates and humans have demonstrated that amphetamine‐induced dopamine release in the cortex can be measured with [11C]FLB 457 and PET imaging. This technique has been successfully used in recent clinical studies to show decreased dopamine transmission in the prefrontal cortex in schizophrenia and alcohol dependence. Here, we present data from a cohort of twelve healthy controls in whom an oral amphetamine challenge (0.5 mg kg−1) did not lead to a significant reduction in [11C]FLB 457 BPND (i.e., binding potential relative to non‐displaceable uptake). Two factors that likely contributed to the inability to displace [11C]FLB 457 BPND in this cohort relative to successful cohorts are: (a) the acquisition of the baseline and post‐amphetamine scans on different days as opposed to the same day and (b) the initiation of the post‐amphetamine [11C]FLB 457 scan at ∼5 hours as opposed to ∼3 hours following oral amphetamine. Furthermore, we show [11C]FLB 457 reproducibility data from a legacy dataset to support greater variability in cortical BPND when the test and retest scans are acquired on different days as compared to the same day. These results highlight the methodological challenges that continue to plague the field with respect to imaging dopamine release in the cortex.
Failure to detect amphetamine‐induced dopamine release in the cortex with [11C]FLB 457 positron emission tomography (PET): Methodological considerations
Studies in nonhuman primates and humans have demonstrated that amphetamine‐induced dopamine release in the cortex can be measured with [11C]FLB 457 and PET imaging. This technique has been successfully used in recent clinical studies to show decreased dopamine transmission in the prefrontal cortex in schizophrenia and alcohol dependence. Here, we present data from a cohort of twelve healthy controls in whom an oral amphetamine challenge (0.5 mg kg−1) did not lead to a significant reduction in [11C]FLB 457 BPND (i.e., binding potential relative to non‐displaceable uptake). Two factors that likely contributed to the inability to displace [11C]FLB 457 BPND in this cohort relative to successful cohorts are: (a) the acquisition of the baseline and post‐amphetamine scans on different days as opposed to the same day and (b) the initiation of the post‐amphetamine [11C]FLB 457 scan at ∼5 hours as opposed to ∼3 hours following oral amphetamine. Furthermore, we show [11C]FLB 457 reproducibility data from a legacy dataset to support greater variability in cortical BPND when the test and retest scans are acquired on different days as compared to the same day. These results highlight the methodological challenges that continue to plague the field with respect to imaging dopamine release in the cortex.
- 1 April 2018
- Published by Elsevier in Biological Psychiatry
- Vol. 83 (8) , 707-714
Amphetamine-Induced Striatal Dopamine Release Measured With an Agonist Radiotracer in Schizophrenia
- 1 April 2018
- Published by Elsevier in Biological Psychiatry
- Vol. 83 (8) , 707-714
Amphetamine-Induced Striatal Dopamine Release Measured With an Agonist Radiotracer in Schizophrenia
An open‐label positron emission tomography study to evaluate serotonin transporter occupancy following escalating dosing regimens of (R)‐(–)‐O‐desmethylvenlafaxine and racemic O‐desmethylvenlafaxine
SEP‐227162 [R(–)‐O‐desmethylvenlafaxine] is an enantiomer of the venlafaxine metabolite O‐desmethylvenlafaxine (ODV, Pristiq™, Wyeth). This study compared the serotonin transporter (SERT) occupancy achieved by SEP‐227162 and ODV, at daily doses of 25, 50, 100, and 150 mg using [11C]DASB positron emission tomography (PET). Sixteen healthy male subjects participated in one of four dose groups (N = 4 per group) during which they were administered two doses of the study drug (SEP‐227162 or ODV). For each study drug, total daily doses of 25, 50, 100, and150 mg were studied. Subjects underwent three PET scans with [11C]DASB. A baseline, off‐medication, scan was performed prior to dosing and a [11C]DASB PET scan was performed after 72 hr at each dose level. [11C]DASB binding potential (BPND) was calculated using the simplified reference tissue method. SERT occupancy was calculated as the change in BPND (ΔBPND) from baseline scan to the on‐medication scan relative to the baseline BPND value. SEP‐227162 and ODV significantly reduced regional distribution volumes and region BPND values in a dose‐dependent manner. Across all doses ODV produced significantly greater SERT occupancy than SEP‐227162 (ANOVA F = 21.8, df = 1,23, p < .001). The total daily dose required to provide 50% SERT occupancy was 24.8 mg for SEP‐227162 and 14.4 mg for ODV. In vitro data suggests a ratio of 3.3:1 for binding at human SERT for SEP‐227162 relative to ODV. Our study suggests a ratio of 1.7:1, highlighting the value of in vivo imaging in the drug development process.
An open‐label positron emission tomography study to evaluate serotonin transporter occupancy following escalating dosing regimens of (R)‐(–)‐O‐desmethylvenlafaxine and racemic O‐desmethylvenlafaxine
SEP‐227162 [R(–)‐O‐desmethylvenlafaxine] is an enantiomer of the venlafaxine metabolite O‐desmethylvenlafaxine (ODV, Pristiq™, Wyeth). This study compared the serotonin transporter (SERT) occupancy achieved by SEP‐227162 and ODV, at daily doses of 25, 50, 100, and 150 mg using [11C]DASB positron emission tomography (PET). Sixteen healthy male subjects participated in one of four dose groups (N = 4 per group) during which they were administered two doses of the study drug (SEP‐227162 or ODV). For each study drug, total daily doses of 25, 50, 100, and150 mg were studied. Subjects underwent three PET scans with [11C]DASB. A baseline, off‐medication, scan was performed prior to dosing and a [11C]DASB PET scan was performed after 72 hr at each dose level. [11C]DASB binding potential (BPND) was calculated using the simplified reference tissue method. SERT occupancy was calculated as the change in BPND (ΔBPND) from baseline scan to the on‐medication scan relative to the baseline BPND value. SEP‐227162 and ODV significantly reduced regional distribution volumes and region BPND values in a dose‐dependent manner. Across all doses ODV produced significantly greater SERT occupancy than SEP‐227162 (ANOVA F = 21.8, df = 1,23, p < .001). The total daily dose required to provide 50% SERT occupancy was 24.8 mg for SEP‐227162 and 14.4 mg for ODV. In vitro data suggests a ratio of 3.3:1 for binding at human SERT for SEP‐227162 relative to ODV. Our study suggests a ratio of 1.7:1, highlighting the value of in vivo imaging in the drug development process.
Brain translocator protein occupancy by ONO‐2952 in healthy adults: A Phase 1 PET study using [11C]PBR28
ONO‐2952, a novel antagonist of translocator protein 18 kDa (TSPO), binds with high affinity to TSPO in rat brain and human tumor cell line membrane preparations. This study used the TSPO‐specific PET radioligand [11 C]PBR28 to confirm binding of ONO‐2952 to brain TSPO in human subjects, and evaluate brain TSPO occupancy and its relationship with ONO‐2952 plasma concentration. Sixteen healthy subjects received a single oral dose of 200, 60, 20, or 6 mg ONO‐2952 (n = 4 per dose). Two PET scans with [11 C]PBR28 were conducted ≤7 days apart: at baseline and 24 h after ONO‐2952 administration. [11 C]PBR28 regional distribution volume (VT) was derived with kinetic modeling using the arterial input function and a two tissue compartment model. Nonspecific binding (VND) was obtained on an individual basis for each subject using linear regression as the x‐intercept of the Lassen plot. The binding potential relative to VND (BPND) was derived as the difference between VT in the ROI (VT ROI) and VND, normalized to VND; BPND = (VT ROI – VND)/VND. TSPO occupancy was calculated as the change in BPND (ΔBPND) from individual's baseline scan to the on‐medication scan to the baseline BPND value. TSPO occupancy by ONO‐2952 was dose dependent between 20–200 mg, approaching saturation at 200 mg both in the whole brain and in 15 anatomic regions of interest (ROI). Estimated Ki values ranged from 24.1 to 72.2 nM. This open‐label, single‐center, single‐dose study demonstrated engagement of ONO‐2952 to brain TSPO. The relationship between pharmacokinetics and TSPO occupancy observed in this study support the hypothesis that ONO‐2952 could potentially modulate neurosteroid production by binding to brain TSPO.
Brain translocator protein occupancy by ONO‐2952 in healthy adults: A Phase 1 PET study using [11C]PBR28
ONO‐2952, a novel antagonist of translocator protein 18 kDa (TSPO), binds with high affinity to TSPO in rat brain and human tumor cell line membrane preparations. This study used the TSPO‐specific PET radioligand [11 C]PBR28 to confirm binding of ONO‐2952 to brain TSPO in human subjects, and evaluate brain TSPO occupancy and its relationship with ONO‐2952 plasma concentration. Sixteen healthy subjects received a single oral dose of 200, 60, 20, or 6 mg ONO‐2952 (n = 4 per dose). Two PET scans with [11 C]PBR28 were conducted ≤7 days apart: at baseline and 24 h after ONO‐2952 administration. [11 C]PBR28 regional distribution volume (VT) was derived with kinetic modeling using the arterial input function and a two tissue compartment model. Nonspecific binding (VND) was obtained on an individual basis for each subject using linear regression as the x‐intercept of the Lassen plot. The binding potential relative to VND (BPND) was derived as the difference between VT in the ROI (VT ROI) and VND, normalized to VND; BPND = (VT ROI – VND)/VND. TSPO occupancy was calculated as the change in BPND (ΔBPND) from individual's baseline scan to the on‐medication scan to the baseline BPND value. TSPO occupancy by ONO‐2952 was dose dependent between 20–200 mg, approaching saturation at 200 mg both in the whole brain and in 15 anatomic regions of interest (ROI). Estimated Ki values ranged from 24.1 to 72.2 nM. This open‐label, single‐center, single‐dose study demonstrated engagement of ONO‐2952 to brain TSPO. The relationship between pharmacokinetics and TSPO occupancy observed in this study support the hypothesis that ONO‐2952 could potentially modulate neurosteroid production by binding to brain TSPO.